Search Result

Results for "

CIT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Linker (101) Akt (1) Amino Acid Derivatives (2) Antibody-Drug Conjugates (ADCs) (6) Apoptosis (2) Autophagy (2) Bacterial (3) Biochemical Assay Reagents (4) Btk (1) c-Kit (1) c-Met/HGFR (1) Caspase (1) CD20 (1) Cytochrome P450 (1) DNA Alkylator/Crosslinker (2) Dopamine Transporter (1) Drug Derivative (2) Drug Intermediate (2) Drug Isomer (1) Drug Metabolite (1) Drug-Linker Conjugates for ADC (92) EGFR (2) Endogenous Metabolite (1) Enterovirus (3) Epigenetic Reader Domain (1) ERK (1) Estrogen Receptor/ERR (1) Influenza Virus (1) Interleukin Related (2) Kinesin (1) Liposome (1) Microtubule/Tubulin (22) MMP (1) NAMPT (1) Nectin-4 (3) Nucleoside Antimetabolite/Analog (1) p38 MAPK (2) Peptide-Drug Conjugates (PDCs) (1) Prostaglandin Receptor (1) PROTAC Linkers (6) PROTAC-Linker Conjugates for PAC (3) Protease Activated Receptor (PAR) (2) Protein Arginine Deiminase (2) PSMA (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Small Interfering RNA (siRNA) (4) Target Protein Ligand-Linker Conjugates (1) Toll-like Receptor (TLR) (2) Topoisomerase (22)
By Research Areas:	Cancer (202) Cardiovascular Disease (3) Endocrinology (2) Infection (3) Inflammation/Immunology (11) Neurological Disease (5)
Click Chemistry:	ADC Synthesis (24) TCO (3) DBCO (11) PROTAC Synthesis (3) Azide (13) BCN (4) Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Cationic Lipids (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

240

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100374

*Val-Cit-PAB-MMAE* 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-41189

*Fmoc-Val-Cit-PAB-PNP*	ADC Linker	Cancer
Fmoc-Val-Cit-PAB-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Fmoc-Val-Cit-PAB-PNP has superior plasma stability comparable to that of non-cleavable linkers .

HY-145929

*MC-Val-Cit-PAB-Exatecan* 1 Publications Verification MC-Val-CIT-PAB-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
MC-Val-Cit-PAB-Exatecan (MC-Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. MC-Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker.

HY-12362

*Val-cit-PAB-OH* 1 Publications Verification	ADC Linker	Cancer
Val-cit-PAB-OH is a degradable ADC linker.

HY-112786

*MC-Val-Cit-PAB-MMAF* 5 Publications Verification Vc-MMAF	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-MMAF (Vc-MMAF) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF (HY-15579), linked via cathepsin cleavable MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB-MMAF shows antitumor activity .

HY-19318

*Fmoc-Val-Cit-PAB*	ADC Linker	Cancer
Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-130989

*SuO-Glu-Val-Cit-PAB-MMAE* NHS-Glutarate-Val-CIT-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
SuO-Glu-Val-Cit-PAB-MMAE (NHS-Glutarate-Val-Cit-PAB-MMAE) consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-153031

*Val-Cit-PAB-Exatecan* Val-CIT-PAB-DX8951	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .

HY-140014

Val-Cit	ADC Linker	Cancer
Val-Cit is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128904

*MC-Val-Cit-PAB-duocarmycin chloride* 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-duocarmycin chloride is a agent-linker conjugate for ADC with potent antitumor activity by using Duocarmycin (a DNA minor groove binding alkylating agent), linked via the ADC linker MC-Val-Cit-PAB.

HY-W190927

*MC-Val-Cit-Doxorubicin* MC-Val-CIT-PAB-Doxorubicin	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-Doxorubicin (MC-Val-Cit-PAB-Doxorubicin) is drug-linker conjugate for ADC. The maleimide can conjugate with thiol containing molecules. Doxorubicin is an anthracycline antibiotic with antineoplastic activity

HY-148245

*OH-Glu-Val-Cit-PAB-MMAE*	Drug-Linker Conjugates for ADC	Cancer
OH-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (OH-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-128902

*MC-Val-Cit-PAB-vinblastine* 1 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-vinblastine is a agent-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

HY-130937

*DBCO-Val-Cit-PABC-PNP*	ADC Linker	Cancer
DBCO-Val-Cit-PABC-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-PNP is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-130990

*DBCO-PEG4-Val-Cit-PAB-MMAF*	Drug-Linker Conjugates for ADC	Cancer
DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-153373

4A3-Cit 1 Publications Verification	Liposome	Others
4A3-Cit is an ionizable lipid used for the generation of lipid nanoparticles (LNPs).

HY-19811

*Fmoc-Val-Cit-PAB-MMAE*	Drug-Linker Conjugates for ADC Microtubule/Tubulin	Cancer
Fmoc-Val-Cit-PAB-MMAE consists the ADCs linker (Fmoc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE). Fmoc-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC.

HY-141141

*Boc-Val-Cit-PAB*	ADC Linker	Cancer
Boc-Val-Cit-PAB is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-W038702

*Boc-Val-Cit-OH*	ADC Linker	Cancer
Boc-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) .

HY-147286

*Ac-Lys-Val-Cit-PABC-MMAE*	Drug-Linker Conjugates for ADC	Cancer
Ac-Lys-Val-Cit-PABC-MMAE is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162) .

HY-100567

*MAL-di-EG-Val-Cit-PAB-MMAE*	Drug-Linker Conjugates for ADC	Cancer
MAL-di-EG-Val-Cit-PAB-MMAE consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin inhibitor (MMAE).

HY-160441

*MC-Val-Cit-PAB-Ispinesib*	Drug-Linker Conjugates for ADC Kinesin	Neurological Disease Cancer
MC-Val-Cit-PAB-Ispinesib (Compound 509) is a drug-linker conjugate for ADC, consisting of a cleavable ADC linker and Eg5 inhibitor. MC-Val-Cit-PAB-Ispinesib can be used for the synthesis of antibody-drug conjugates (ADCs) .

HY-78736

*Val-Cit-PAB-OSBT*	ADC Linker	Cancer
Val-Cit-PAB-OSBT is a degradable ADC linker composed of the peptide Val-Cit-PAB and the OSBT group, which ensures stable performance during targeted drug delivery .

HY-141860

*PSMA-Val-Cit-PAB-MMAE*	PSMA Microtubule/Tubulin Reactive Oxygen Species (ROS) Cytochrome P450	Cancer
PSMA-Val-Cit-PAB-MMAE is a small-molecule conjugate targeting PSMA, with Monomethyl auristatin E (MMAE) (HY-15162) as its cytotoxic payload. PSMA-Val-Cit-PAB-MMAE binds to PSMA, thereby being delivered into PSMA-expressing prostate cancer cells. Subsequently, the Val-Cit linker is cleaved under the mediation of cathepsin B, releasing active MMAE. PSMA-Val-Cit-PAB-MMAE inhibits CYP3A4 activity (IC₅₀ = 11.2 μM), induces intracellular ROS production and oxidative stress, disrupts the cytoskeleton through microtubule destabilization, and induces prostate cancer cell death. PSMA-Val-Cit-PAB-MMAE can be used in research related to prostate cancer .

HY-100566

*SuO-Val-Cit-PAB-MMAE* 3 Publications Verification	Drug-Linker Conjugates for ADC	Cancer
SuO-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the peptide SuO-Val-Cit-PAB .

HY-158137

*Val-Cit-PAB-DEA-Dxd*	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-DEA-Dxd (compound 81) is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (DNA topoisomerase I inhibitor). Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis .

HY-W591408

*DBCO-Val-Cit-PAB-MMAE*	Drug-Linker Conjugates for ADC	Cancer
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .

HY-172287

*DBCO-PEG2-Val-Cit-PAB-MMAE*	ADC Linker	Cancer
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

HY-44177

*Val-Cit-PAB-MMAF sodium*	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF sodium is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAF sodium contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin polymerization inhibitor MMAF (HY-15579)

HY-171931A

*Aminocaproyl-Val-Cit-PABC-Exatecan TFA*	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan TFA is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan TFA can be used for ADC molecues synthesis .

HY-W008064

*Fmoc-Cit-OH* Fmoc-L-CITrulline	Amino Acid Derivatives	Cancer
Fmoc-Cit-OH (Fmoc-L-Citrulline) is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize a degradable ADC linker composed of a valine-citrulline (Val-Cit) motif .

HY-128711

*MAL-di-EG-Val-Cit-PAB-MMAF*	Drug-Linker Conjugates for ADC	Cancer
MAL-di-EG-Val-Cit-PAB-MMAF consists the ADCs linker (MAL-di-EG-Val-Cit-PAB) and potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F) .

HY-19813A

*mDPR-Val-Cit-PAB-MMAE TFA*	Drug-Linker Conjugates for ADC	Cancer
mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition ^{[1] ^.}

HY-139726

*Mal-PEG4-Val-Cit-PAB-MMAE*	Drug-Linker Conjugates for ADC	Cancer
Mal-PEG4-Val-Cit-PAB-MMAE is part of a drug-linker conjugate for ADC. Mal-PEG4-Val-Cit-PAB-MMAE contains a degradable ADC linker Mal-PEG4-Val-Cit-PAB (HY-126672) and a potent tubulin inhibitor MMAE (HY-15162) .

HY-153031A

*Val-Cit-PAB-Exatecan TFA* Val-CIT-PAB-DX8951 TFA	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Val-Cit-PAB-Exatecan (Val-Cit-PAB-DX8951) TFA is a agent-linker conjugate for ADC. Val-Cit-PAB-Exatecan TFA is composed of a DNA topoisomerase I DX-8951 (HY-13631) and a cathepsin cleavable ADC linker .

HY-177599

*Boc-Val-Cit-PAB-MMAE*	Drug-Linker Conjugates for ADC	Cancer
Boc-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC, which is composed of a linker Boc-Val-Cit-PAB (HY141141) and a Microtubule inhibitor MMAE (HY-15162). Boc-Val-Cit-PAB-MMAE can be used for ADC synthesis.

HY-171931

*Aminocaproyl-Val-Cit-PABC-Exatecan*	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Aminocaproyl-Val-Cit-PABC-Exatecan is a drug-linker conjugate for ADC, consiting of a cleavable linker (Aminocaproyl-Val-Cit-PABC) and Exatecan (HY-13631) (topoisomerase I inhibitor). Aminocaproyl-Val-Cit-PABC-Exatecan can be used for ADC molecues synthesis .

HY-78738G

MC-Val-Cit-PAB	ADC Linker	Cancer
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

HY-128908

*MC-Val-Cit-PAB-Indibulin*	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-Indibulin is a agent-linker conjugate for ADC with potent antitumor activity by using Indibulin (an orally applicable inhibitor of tubulin assembly), linked via the ADC linker MC-Val-Cit-PAB.

HY-160774

*Val-Cit-PABC-DOX*	Drug-Linker Conjugates for ADC Topoisomerase	Cancer
Val-Cit-PABC-DOX (compound 10109), an epsilon-poly-L-lysine-based drug conjugate, is an agent-linker conjugate for ADC by using a DNA topoisomerase I and topoisomerase II inhibitor, Doxorubicin (HY-15142), linked via the linker, Val-Cit-PABC .

HY-177681

*N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)*	Drug-Linker Conjugates for ADC Topoisomerase Microtubule/Tubulin	Cancer
N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.

HY-W190913

*DBCO-PEG4-Val-Cit-PAB-PNP*	ADC Linker	Cancer
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.

HY-101909

*Val-Cit-PAB-MMAF*	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAF is a drug-Linker conjugates for ADC. Val-Cit-PAB-MMAF is composed of an ADC linker (peptide Val-Cit-PAB) and a potent microtubule polymerization inhibitor MMAF (HY-15579) .

HY-160694

*cBu-Cit-GAL-02-221* cBu-CIT-PROTAC BRD4 Degrader-5	PROTAC-Linker Conjugates for PAC Epigenetic Reader Domain	Cancer
cBu-Cit-GAL-02-221 is a PROTAC that degrades BRD4 by association with cBu-Cit. cBu-Cit-GAL-02-221 can effectively inhibit BRD4 in HER2 positive and negative breast cancer cell lines. cBu-Cit-GAL-02-221 has a single bond and can be conjugated to an ADC antibody to form a PAC .

HY-128906

*MC-Val-Cit-PAB-Retapamulin*	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-Retapamulin is a agent-linker conjugate for ADC with potent antitumor activity by using Retapamulin (a ribosome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

HY-111121

*cBu-Cit-OH* Mal-cyclobutane-1,1-dicarboxamide-CIT-PAB	ADC Linker	Cancer
cBu-Cit-OH (Mal-cyclobutane-1) is an ADC Linker that can be used to synthesize ADCs .

HY-128903

*MC-Val-Cit-PAB-carfilzomib iodide*	Drug-Linker Conjugates for ADC	Cancer
MC-Val-Cit-PAB-carfilzomib iodide is a agent-linker conjugate for ADC with potent antitumor activity by using carfilzomib (an irreversible proteasome inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

HY-148326

*Glu(OtBu)-Val-Cit-PAB-OH*	ADC Linker	Others
Glu(OtBu)-Val-Cit-PAB-OH (compound L5-1c) is an non-cleavable ADC linker. Glu(OtBu)-Val-Cit-PAB-OH has been used to synthesis protein-tubulysin conjugates .

HY-130936

*DBCO-Val-Cit-PABC-OH*	ADC Linker	Cancer
DBCO-Val-Cit-PABC-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-OH is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-100374G

Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

Cat. No.	Product Name	Type

HY-P99016B

Enfortumab vedotin-ejfv (solution)

1 Publications Verification

Fluorescent Dye

Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-P99016A

Enfortumab vedotin-ejfv

1 Publications Verification

Fluorescent Dye

Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-15575G

VcMMAE MC-Val-CIT-PAB-MMAE; mc-vc-PAB-MMAE	Fluorescent Dye
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

HY-78738G

MC-Val-Cit-PAB	Fluorescent Dye
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

HY-100374G

Val-Cit-PAB-MMAE	Fluorescent Dye
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-12362G

Val-cit-PAB-OH	Fluorescent Dye
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.

HY-20336G

Mc-Val-Cit-PABC-PNP	Fluorescent Dye
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78736G

Val-Cit-PAB-OSBT	Fluorescent Dye
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .

HY-19318G

Fmoc-Val-Cit-PAB	Fluorescent Dye
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

Cat. No.	Product Name	Type

HY-15575G

VcMMAE MC-Val-CIT-PAB-MMAE; mc-vc-PAB-MMAE	Biochemical Assay Reagents
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

HY-153373

4A3-Cit 1 Publications Verification	Biochemical Assay Reagents
4A3-Cit is an ionizable lipid used for the generation of lipid nanoparticles (LNPs).

HY-Y1191

EEDQ EEDQ	Biochemical Assay Reagents
EEDQ is a carboxylate activator and irreversible antagonist of 5HT2c receptors. EEDQ reduces [ ³H]β-CIT binding to the dopamine transporter (DAT) in rat caudate-putamen (CPu) homogenates (IC₅₀ = 78.3 μM). EEDQ inhibits contralateral rotation behavior .

HY-78738G

MC-Val-Cit-PAB	Biochemical Assay Reagents
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

HY-100374G

Val-Cit-PAB-MMAE	Biochemical Assay Reagents
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-12362G

Val-cit-PAB-OH	Biochemical Assay Reagents
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.

HY-20336G

Mc-Val-Cit-PABC-PNP	Biochemical Assay Reagents
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78736G

Val-Cit-PAB-OSBT	Biochemical Assay Reagents
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .

HY-19318G

Fmoc-Val-Cit-PAB	Biochemical Assay Reagents
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

Cat. No.	Product Name	Target	Research Area

HY-W016733

D-Citrulline H-D-CIT-OH	Endogenous Metabolite	Cardiovascular Disease
D-Citrulline (H-D-Cit-OH) is a stereoisomer of L-citrulline (HY-N0391). D-Citrulline significantly attenuates polymorphonuclear leukocyte (PMN)-induced cardiac contractile dysfunction in the isolated perfused rat heart subjected to ischemia/reperfusion via a non-NO-mediated mechanism .

HY-W008064

*Fmoc-Cit-OH* Fmoc-L-CITrulline	Amino Acid Derivatives	Cancer
Fmoc-Cit-OH (Fmoc-L-Citrulline) is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize a degradable ADC linker composed of a valine-citrulline (Val-Cit) motif .

HY-P5372A

*Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA*	Protease Activated Receptor (PAR)	Cancer
Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2 TFA, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type' .

HY-P4160

PDC31 THG113.31; ILGHXDYK	Prostaglandin Receptor	Endocrinology
PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca ²⁺-dependent large-conductance K ⁺-channel in human myometrial cells .

HY-P4007

*[Pmp1,DTyr(OEt)2,Val4,Cit8] Vasopressin*	Drug Isomer	Endocrinology
[Pmp1,DTyr(OEt)2,Val4,Cit8] Vasopressin is an analogue of Vasopressin.

HY-178489

BGC1614	Nectin-4	Cancer
BGC1614 is a Nectin-4-targeting bicyclic toxin conjugate (BTC) belonging to the category of peptide-drug conjugates (PDCs). BGC1614 exhibits strong targeted binding ability to Nectin-4, with an K_D of 3.859 × 10 ^-7 M. BGC1614 exhibits superior antitumor efficacy in nude mice bearing PC-3 and N87 tumor xenografts. BGC1614 can be used for research related to Nectin-4-overexpressing tumors (such as prostate cancer, gastric cancer) .

HY-138106

*Fmoc-D-Cit-OH*	Amino Acid Derivatives	Others
Fmoc-D-Cit-OH is citrulline with an Fmoc protecting group, which can be used to synthesize bioactive peptide mimetics, such as H-Dmt-D-Cit-Aba-b-Ala-NMe-30,50-(CF3)2-Bn and H-Dmt-D-Cit-Aba-b-Ala-NMe-Bn with neurokinin-1 antagonist activity .

HY-P5372

*Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2*	Protease Activated Receptor (PAR)	Cancer
Ala-parafluoroPhe-Arg-Cha-Cit-Tyr-NH2, a bioactive peptide, is a selective Protease activating receptor 1 (PAR-1) agonist over PAR-2. PAR-1 belongs to a subfamily of G-protein coupled receptors and is known to mediate the cellular effects of thrombin. In addition to its varied cellular effects of thrombin, PAR-1 has also been shown to coordinate with PAR-4 and regulate thrombin-induced hepatocellular carcinoma harboring thrombin formation within the tumor environment classified as 'coagulation type' .

HY-P10775

BT1769	Peptide-Drug Conjugates (PDCs) MMP	Cancer
BT1769 is a MT1-MMP-targeted (K_D = 3.35 nM) Bicycle toxin conjugate. BT1769 can be used in the study for osteosarcoma. BT1769 consists of a novel bicyclic targeting peptide that selectively binds MT1-MMP; a cytotoxin MMAE; and an enzymatically cleavable dipeptide linker .

HY-P5843

Citrullinated LL-37 4cit	Enterovirus	Infection
Citrullinated LL-37 3cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 3cit lacks all antiviral activity at 10 μg/mL and retains some activity against HRV at 30 μg/mL. Citrullinated LL-37 3cit reduces the immunomodulatory activity of LL-37. Citrullinated LL-37 3cit shows a moderate loss in the ability to reduce HRV-induced CCL5 secretion .

HY-P5836

Citrullinated LL-37 1cit	Interleukin Related Bacterial Enterovirus	Inflammation/Immunology
Citrullinated LL-37 1cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 1cit does not alter the antiviral effect of LL-37 toward human rhinovirus. Citrullinated LL-37 1cit shows antibacterial activity toward S. aureus. Citrullinated LL-37 1cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B .

HY-P5838

Citrullinated LL-37 5cit	Bacterial	Inflammation/Immunology
Citrullinated LL-37 5cit is a citrullinated LL-37 (HY-P1222) peptide. The antiviral and antibacterial effects of Citrullinated LL-37 5cit are significantly reduced compared to native LL-37. Citrullinated LL-37 5cit is unable to reduce LPS-mediated release of TNF-α due to a lack of LPS-binding capacity .

HY-P5837

Citrullinated LL-37 2cit	Interleukin Related Enterovirus	Inflammation/Immunology
Citrullinated LL-37 2cit is a citrullinated LL-37 (HY-P1222) peptide. Citrullinated LL-37 2cit reduces LL-37 activity against HRV at 10 μg/mL and reduces the antibacterial effect of LL-37. Citrullinated LL-37 2cit causes a reduction in the levels of IL-8, CCL5, and IL-6 mRNA induced by RV1B. Citrullinated LL-37 2cit shows a moderate loss in the ability to reduce HRV-induced CCL5 secretion .

HY-P5842

Citrullinated LL-37 3cit	Bacterial Influenza Virus	Infection
Citrullinated LL-37 3cit is a host defense peptide (HDP) with broad immunomodulatory and antimicrobial activities. Citrullinated LL-37 3cit exhibits direct antiviral effects against human rhinoviruses (HRV) .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99016B

Enfortumab vedotin-ejfv (solution) 1 Publications Verification	Antibody-Drug Conjugates (ADCs) Nectin-4	Cancer
Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .

HY-164154

ADC Control Human IgG1-vcMMAF	Antibody-Drug Conjugates (ADCs) Microtubule/Tubulin	Cancer
ADC Control Human IgG1-vcMMAF is a humanized monoclonal antibody that is an isotype control of ADC human IgG1-vcMMAF and can inhibit tubulin polymerization. The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is MC-Val-Cit-PAB-MMAF (vcMMAF; HY-112786) .

HY-P992332

CIT-013

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P702636

	CIT Protein, Human (Active, sf9) CIT; CITron (rho-interacting, serine/threonine kinase 21); CITron Rho-interacting kinase; CRIK; KIAA0949; STK21; serine/threonine-protein kinase 21	Human	Sf9 insect cells
	CIT Protein, Human (sf9) is the recombinant human-derived CIT, expressed by Sf9 insect cells , with tag Free labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-15575S

VcMMAE-d8
VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc) .

Cat. No.	Product Name		Classification

HY-140150

*Azido-PEG3-Val-Cit-PAB-PNP*		Azide PROTAC Synthesis ADC Synthesis
Azido-PEG3-Val-Cit-PAB-PNP is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG3-Val-Cit-PAB-PNP is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Azido-PEG3-Val-Cit-PAB-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-130937

*DBCO-Val-Cit-PABC-PNP*		DBCO ADC Synthesis
DBCO-Val-Cit-PABC-PNP is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-PNP is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-130990

*DBCO-PEG4-Val-Cit-PAB-MMAF*		ADC Synthesis DBCO
DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-141155

*endo-BCN-PEG4-Val-Cit-PAB-MMAE* 1 Publications Verification		ADC Synthesis BCN
endo-BCN-PEG4-Val-Cit-PAB-MMAE is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

HY-W190943

*Azido-PEG4-Val-Cit-PAB-MMAE* 1 Publications Verification		Azide ADC Synthesis
Azido-PEG4-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker Azido-PEG4-Val-Cit-PAB-OH . Azido-PEG4-Val-Cit-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-19812

*Acetylene-linker-Val-Cit-PABC-MMAE* LCB14-0602		ADC Synthesis Alkynes
Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) consists the ADCs linker (Acetylene-linker-Val-Cit-PABC) and potent tubulin inhibitor (MMAE). Acetylene-linker-Val-Cit-PABC-MMAE (LCB14-0602) is a agent-linker conjugate for ADC. Acetylene-linker-Val-Cit-PABC-MMAE is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W591408

*DBCO-Val-Cit-PAB-MMAE*		DBCO
DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group .

HY-172287

*DBCO-PEG2-Val-Cit-PAB-MMAE*		DBCO
DBCO-PEG2-Val-Cit-PAB-MMAE is an ADC linker featuring a DBCO group, a Val-Cit dipeptide, a PAB motif, and an MMAE warhead. The DBCO group is a click chemistry handle which readily reacts with azide groups, while the Val-Cit is a protease-cleavable dipeptide which releases the MMAE warhead into cells via an elimination mechanism.

HY-164309

*DBCO-PEG3-Glu-Val-Cit-PABC-MMAE*		DBCO
DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC .

HY-130923

*BCN-PEG1-Val-Cit-PABC-OH*		BCN ADC Synthesis
BCN-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-151726

*Azido-PEG(4)-Val-Cit-PAB-PNP*		Azide
Azido-PEG(4)-Val-Cit-PAB-PNP is a cleavable peptide ADC linker. Azido-PEG(4)-Val-Cit-PAB-PNP is a click chemistry reagent containing an azide group. It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-W190913

*DBCO-PEG4-Val-Cit-PAB-PNP*		DBCO
DBCO-PEG4-Val-Cit-PAB-PNP is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. PNP can be substituted by amine-containing payload. DBCO enable click chemistry with azide molecules.

HY-130936

*DBCO-Val-Cit-PABC-OH*		ADC Synthesis DBCO
DBCO-Val-Cit-PABC-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-PABC-OH is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-130966

*TCO-PEG1-Val-Cit-PABC-OH*		TCO ADC Synthesis
TCO-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . TCO-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

HY-140149

*Azido-PEG4-Val-Cit-PAB-OH*		PROTAC Synthesis ADC Synthesis Azide
Azido-PEG4-Val-Cit-PAB-OH is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG4-Val-Cit-PAB-OH is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs . Azido-PEG4-Val-Cit-PAB-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-130935

*DBCO-Val-Cit-OH*		ADC Synthesis DBCO
DBCO-Val-Cit-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-Val-Cit-OH is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136100

*TCO-PEG1-Val-Cit-PABC-PNP*		TCO ADC Synthesis
TCO-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). TCO-PEG1-Val-Cit-PABC-PNP is a click chemistry reagent, which contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups .

HY-151709A

*N3-L-Cit-OH (DCHA)*		Azide ADC Synthesis
N3-L-Cit-OH DCHA is a click chemistry reagent containing an azide group. N3-L-Cit-OH DCHA can be used to construct peptidomimetic ADC linkers using Click-chemistry . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-140148

*Azido-PEG3-Val-Cit-PAB-OH*		ADC Synthesis Azide
Azido-PEG3-Val-Cit-PAB-OH is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG3-Val-Cit-PAB-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-136105

*Azido-PEG1-Val-Cit-PABC-PNP*		ADC Synthesis Azide
Azido-PEG1-Val-Cit-PABC-PNP is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG1-Val-Cit-PABC-PNP is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-126676

*DBCO-(PEG2-Val-Cit-PAB)2*		PROTAC Synthesis ADC Synthesis DBCO
DBCO-(PEG2-Val-Cit-PAB)2 is a dual cleavable ADC linker for antibody-drug conjugates (ADCs). DBCO-(PEG2-Val-Cit-PAB)2 is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. DBCO-(PEG2-Val-Cit-PAB)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136098

*DBCO-PEG4-acetic-Val-Cit-PAB*		ADC Synthesis DBCO
DBCO-PEG4-acetic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-acetic-Val-Cit-PAB is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-136103

*DBCO-PEG4-Propionic-Val-Cit-PAB*		DBCO ADC Synthesis
DBCO-PEG4-Propionic-Val-Cit-PAB is a cleavable 4 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . DBCO-PEG4-Propionic-Val-Cit-PAB is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-151699

*6-Azidohexanoyl-Val-Cit-PAB-PNP*		Azide
6-Azidohexanoyl-Val-Cit-PAB-PNP is a click chemistry reagent that can be used to synthesis It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-W947216

*BCN-sulfamoyl-PEG2-sulfamoyl-bis(Val-Cit-PAB-Exatecan)*		ADC Synthesis

HY-130922

*BCN-PEG1-Val-Cit-OH*		ADC Synthesis BCN
BCN-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . BCN-PEG1-Val-Cit-OH is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

HY-130934

*TCO-PEG1-Val-Cit-OH*		TCO ADC Synthesis
TCO-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . TCO-PEG1-Val-Cit-OH is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.

HY-151709

*N3-L-Cit-OH*		Azide ADC Synthesis
N3-L-Cit-OH is a click chemistry reagent containing an azide group. N3-L-Cit-OH can be used to construct peptidomimetic ADC linkers using Click-chemistry . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-W800814

*Azido-PEG8-Amido-Val-Cit-PAB*		Azide
Azido-PEG8-Amido-Val-Cit-PAB is a cleavable ADC linker. The Val-Cit will specifically be cleaved by Cathepsin B. As this enzyme is only present in the lysosome, the ADC payload will be released only in the cell. Azido will react with DBCO, BCN or other alkyne groups through click chemistry. PEG spacer increases aqueous solubility. Reagent grade, for research purpose.

HY-136034

*Azido-PEG1-Val-Cit-OH*		ADC Synthesis Azide
Azido-PEG1-Val-Cit-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azido-PEG1-Val-Cit-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-136137

*Azide-PEG1-Val-Cit-PABC-OH*		ADC Synthesis Azide
Azide-PEG1-Val-Cit-PABC-OH is a cleavable 1 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) . Azide-PEG1-Val-Cit-PABC-OH is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-151700

*6-Azidohexanoyl-Val-Cit-PAB*		Azide
6-Azidohexanoyl-Val-Cit-PAB is a click chemistry reagent that can be used to synthesis vaccine . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.

HY-W590556

*Endo-BCN-PEG4-Val-Cit-PAB-MMAF*		BCN
Endo-BCN-PEG4-Val-Cit-PAB-MMAF is a cleavable ADC linker conjugated with drug containing 4-unit PEG, which can be used for synthesizing antibody-drug conjugates (ADCs). endo-BCN-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a BCN group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-78736G

Val-Cit-PAB-OSBT	ADC Linker	Cancer
Val-Cit-PAB-OSBT GMP is a GMP grade Val-Cit-PAB-OSBT (HY-78736). Val-Cit-PAB-OSBT is a degradable ADC linker, which is composed of the polypeptide Val-Cit-PAB and OSBT groups coupled together .

HY-100374G

Val-Cit-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.

HY-19318G

Fmoc-Val-Cit-PAB	ADC Linker	Cancer
Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.

HY-12362G

Val-cit-PAB-OH	ADC Linker	Cancer
Val-cit-PAB-OH GMP is a GMP grade Val-cit-PAB-OH (HY-12362). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Val-cit-PAB-OH is a degradable ADC linker.

HY-20336G

Mc-Val-Cit-PABC-PNP	ADC Linker	Cancer
Mc-Val-Cit-PABC-PNP GMP is a GMP grade Mc-Val-Cit-PABC-PNP (HY-20336). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC linker. Mc-Val-Cit-PABC-PNP can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-78738G

MC-Val-Cit-PAB	ADC Linker	Cancer
MC-Val-Cit-PAB GMP is a GMP grade MC-Val-Cit-PAB (HY-78738). MC-Val-Cit-PAB is an intermediate in the synthesis of VcMMAE (HY-15575), which is a Drug-Linker Conjugates for ADC. Monomethyl auristatin E can be used to inhibit Microtubule/Tubulin as ADC Cytotoxin.

HY-15575G

VcMMAE MC-Val-CIT-PAB-MMAE; mc-vc-PAB-MMAE	Drug-Linker Conjugates for ADC	Cancer
VcMMAE (MC-Val-Cit-PAB-MMAE) (GMP) is VcMMAE (HY-15575) produced by using GMP guidelines. VcMMAE is a drug-linker conjugate for ADC .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: